TY - JOUR
T1 - Effect of weight reductions on estimated kidney function
T2 - Post-hoc analysis of two randomized trials
AU - von Scholten, Bernt Johan
AU - Davies, Melanie J
AU - Persson, Frederik
AU - Hansen, Tine W
AU - Madsbad, Sten
AU - Endahl, Lars
AU - Jepsen, Cecilie H
AU - Rossing, Peter
N1 - Copyright © 2017 Elsevier Inc. All rights reserved.
PY - 2017/7
Y1 - 2017/7
N2 - AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.
AB - AIMS: Weight loss-induced serum creatinine reduction may increase creatinine-based estimated glomerular filtration rate (eGFR) producing incorrect estimates of kidney function. We investigated whether weight changes in the SCALE program with liraglutide 3.0mg were associated with changes in serum creatinine.METHODS: Post hoc analysis of two 56-week, randomized, double-blind trials: SCALE Obesity and Prediabetes (n=3731, without type 2 diabetes [T2D], randomized [2:1] to liraglutide 3.0mg [n=2487] or placebo [n=1244]); SCALE Diabetes (n=846 with T2D, randomized [2:1:1] to liraglutide 3.0mg [n=423], 1.8mg [n=211, excluded from this analysis] or placebo [n=212]). NCT01272219/NCT01272232.RESULTS: In SCALE Obesity and Prediabetes, mean (±SD) weight loss (baseline to week 56) with liraglutide was 8.0±6.7% (2.6±6.9% with placebo); baseline creatinine with liraglutide was 76±15μmol/L and 74±15μmol/L after 56weeks (similar across treatment groups). In SCALE Diabetes, weight loss with liraglutide was 5.9±5.5% (2.0±4.3% with placebo); baseline creatinine was 79±19μmol/L (77±16μmol/L, placebo) and 79±20μmol/L after 56weeks (76±15μmol/L, placebo). No association between changes in weight and changes in serum creatinine was observed (P≥0.05, both trials, all tests).CONCLUSIONS: Moderate gradual body weight reductions observed in the SCALE program were not associated with changes in serum creatinine.
KW - Adult
KW - Anti-Obesity Agents/adverse effects
KW - Biomarkers/blood
KW - Body Mass Index
KW - Combined Modality Therapy/adverse effects
KW - Creatinine/blood
KW - Diabetes Mellitus, Type 2/blood
KW - Diabetic Nephropathies/chemically induced
KW - Double-Blind Method
KW - Female
KW - Glomerular Filtration Rate/drug effects
KW - Glycated Hemoglobin A/analysis
KW - Humans
KW - Hypoglycemic Agents/adverse effects
KW - Kidney/drug effects
KW - Liraglutide/adverse effects
KW - Male
KW - Middle Aged
KW - Obesity/complications
KW - Prediabetic State/blood
KW - Renal Insufficiency/chemically induced
KW - Weight Loss/drug effects
U2 - 10.1016/j.jdiacomp.2017.04.003
DO - 10.1016/j.jdiacomp.2017.04.003
M3 - Journal article
C2 - 28462892
SN - 1056-8727
VL - 31
SP - 1164
EP - 1168
JO - Journal of Diabetes and its Complications
JF - Journal of Diabetes and its Complications
IS - 7
ER -
